GH Key Statistics, Chart & Performance
The current stock price of GH is 106.15 USD. In the past month the price decreased by -5.5%. In the past year, price increased by 138.7%.
GH Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 95.6% of all stocks.
GH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GH. The financial health of GH is average, but there are quite some concerns on its profitability.
GH Financial Highlights
Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -3.26. The EPS increased by 1.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GH Forecast & Estimates
33 analysts have analysed GH and the average price target is 117.9 USD. This implies a price increase of 11.07% is expected in the next year compared to the current price of 106.15.
For the next year, analysts expect an EPS growth of 26.36% and a revenue growth 32.85% for GH
GH Ownership
GH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.39 | 95.512B | ||
| CI | THE CIGNA GROUP | 8.68 | 72.582B | ||
| LH | LABCORP HOLDINGS INC | 15.32 | 22.894B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.26 | 22.748B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.04 | 21.05B | ||
| DVA | DAVITA INC | 10.74 | 10.029B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 27.27 | 6.723B | ||
| CHE | CHEMED CORP | 17.25 | 6.284B | ||
| HIMS | HIMS & HERS HEALTH INC | 41.72 | 5.555B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GH
Company Profile
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Company Info
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063 US
CEO: Helmy Eltoukhy
Employees: 1999
Phone: 18556988887
GUARDANT HEALTH INC / GH FAQ
What does GUARDANT HEALTH INC do?
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
What is the current price of GH stock?
The current stock price of GH is 106.15 USD. The price decreased by -6.1% in the last trading session.
Does GH stock pay dividends?
GH does not pay a dividend.
What is the ChartMill rating of GUARDANT HEALTH INC stock?
GH has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about GUARDANT HEALTH INC (GH) stock?
33 analysts have analysed GH and the average price target is 117.9 USD. This implies a price increase of 11.07% is expected in the next year compared to the current price of 106.15.
What is the employee count for GH stock?
GUARDANT HEALTH INC (GH) currently has 1999 employees.